The aim of the study was to examine how blood pressure is affected by carotid endarterectomy over a 2-year period. We analyzed the data from 997 patients who received best medical care alone and 999 patients who received best medical care plus carotid endarterectomy (CE). All patients were recruited by the North American Symptomatic Carotid Endarterectomy Trial and were followed at regular clinic visits. The mean blood pressure at baseline was 145.2/81.2 mm Hg for medically treated patients and 146.2/81.9 mm Hg for surgically treated patients. The mean systolic and diastolic pressures increased by approximately 2.5% in the first month following randomization, then decreased over the next year and then remained relatively uniform. Throughout follow-up, surgical patients had slightly higher blood pressures than medically treated patients. At the end of 2 years, the mean systolic pressures in the two treatment groups converged to 147.6 mm Hg. The mean diastolic pressure in the medical patients returned to its baseline value, whereas the surgical patients’ blood pressure remained slightly elevated by 0.5 mm Hg. The percentage of patients on antihypertensive medications mirrored the rise and fall in blood pressures. A sharp decrease in medication (from 56 to 43%) was observed in both treatment groups at 1 month. The percentage of patients on medication increased subsequently, with approximately 63% taking medication at the end of 2 years. CE does not affect long-term blood pressure. The use of antihypertensive medications appears to be the key component in blood pressure management. As hypertension is related to neurologic morbidity and mortality, strict regulation of blood pressure is extremely important in patients with cerebrovascular disease.

Keywords:
Carotid artery stenosis, Blood pressure, Carotid endarterectomy
1.
Lehv MS, Salzman EW, Silen W: Hypertension complicating carotid endarterectomy. Stroke 1970;1:307–313.
2.
Angell-James JE, Lumley JSP: The effects of carotid endarterectomy on the mechanical properties of the carotid sinus and carotid sinus nerve activity in atherosclerotic patients. Br J Surg 1974;61:805–810.
3.
Satiani B, Vasko JS, Evans WE: Hypertension following carotid endarterectomy. Surg Neurol 1979;11:357–359.
4.
Bove EL, Fry WJ, Gross WS, Stanley JC: Hypotension and hypertension as consequences of baroreceptor dysfunction following carotid endarterectomy. Surgery 1979;85:633–637.
5.
Towne JB, Bernhard VM: The relationship of postoperative hypertension to complications following carotid endarterectomy. Surgery 1980;88:575–579.
6.
Cafferata HT, Merchant RF, DePalma RG: Avoidance of postcarotid endarterectomy hypertension. Ann Surg 1982;196:465–471.
7.
Asiddao CB, Donegan JH, Whitesell RC, Kalbfleisch JH: Factors associated with perioperative complications during carotid endarterectomy. Anesth Analg 1982;61:631–637.
8.
Ahn SS, Marcus DR, Moore WS: Post-carotid endarterectomy hypertension: Association with elevated cranial norepinephrine. J Vasc Surg 1989;9:351–360.
9.
Asmar RG, Julia PL, Mascarel VL, Fabiani JN, Benetos A, Safar ME: Ambulatory blood pressure profile after carotid endarterectomy in patients with ischaemic arterial disease. J Hypertens 1994;12:697–702.
10.
Hans SS, Glover JL: The relationship of cardiac and neurological complications to blood pressure changes following carotid endarterectomy. Am Surg 1995;61:356–359.
11.
Moore WS, Hall AD: Pathogenesis of arterial hypertension after occlusion of cerebral arteries. Surg Gynecol Obstet 1970;131:885–893.
12.
Dehn TCB, Angell-James JE: Long-term effect of carotid endarterectomy on carotid sinus baroreceptor function and blood pressure control. Br J Surg 1987;74:997–1000.
13.
Tyden G, Samnegard H, Melcher A, Thulin L: Effect of carotid endarterectomy on the antihypertensive properties of the carotid sinus reflex. Acta Chir Scand 1981;147:15–17.
14.
North American Symptomatic Carotid Endarterectomy Trial Collaborators: Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445–453.
15.
North American Symptomatic Carotid Endarterectomy Trial (NASCET) Steering Committee: North American Symptomatic Carotid Endarterectomy Trial: Methods, patient characteristics and progress. Stroke 1991;22:711–720.
16.
Dixon WJ, Brown MB, Engelman L: BMDP Statistical Software. Berkeley, University of California Press, 1990, p 769.
17.
Wade JG, Larson CP, Hickey RF, Ehrenfeld WK, Severinghaus JW: Effect of carotid endarterectomy on carotid chemoceptor and baroreceptor function in man. N Engl J Med 1970;282:823–829.
18.
Appenzeller O, Descarries L: Circulatory reflexes in patients with cerebrovascular disease. N Engl J Med 1964;271:820–823.
19.
Vlachakis ND, Mendlowitz M, De Gusman DD: Diminished baroreceptor sensitivity of elderly hypertensives: Possible role of atherosclerosis. Atherosclerosis 1976;24:243–249.
20.
Beevers DG, Hamilton M, Fairman MJ, Harpur JE: Antihypertensive treatment and the course of established cerebral vascular disease. Lancet 1973;i:1407–1409.
21.
Freis ED: The Veterans Administration cooperative study on antihypertensive agents: Implications for stroke prevention. Stroke 1974;5:76–77.
22.
Frohlich ED: Mild essential hypertension: Benefit of treatment. Ann NY Acad Sci 1978;304:68–73.
23.
Spence JD: Stepped care is dead, but what will replace it? Can Med Assoc J 1989;140:1133–1136.
24.
Spence JD: Recognizing and treating hypertensive emergencies. Can J Diagnosis 1992;9:72–93.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.